PacBio's Revio Systems Chosen By National Institute On Aging Long Life Family Study To Sequence Genomes Of 7,800 Participants In Longevity Study

Author: Benzinga Newsdesk | October 08, 2025 08:19am

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging's Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as many as 7,800 participants. The effort will employ PacBio's Revio systems to capture highly accurate HiFi long-read sequencing data designed to shed light on why longevity runs in families and what drives healthier aging.

The Long Life Family study is a longitudinal multicenter study focused on identifying a range of factors that contribute to healthy aging and survival. This collaboration marks a next-generation upgrade to LLFS's existing genomic resources. To date, the study has enrolled 5,438 individuals across 539 three-generational pedigrees in the U.S. and Denmark and conducted three major rounds of in-home phenotypic visits spanning a period of nearly 20 years.¹ PacBio's HiFi long-read technology delivers highly accurate reads exceeding 15kb, enabling detection of structural variants, repeat expansions, insertions, and phased haplotypes often missed by short reads. Its methylation-aware protocols also permit direct profiling of 5- methylcytosine signatures in native DNA. By applying this approach across thousands of deeply phenotyped LLFS samples, the project aims to:

• Identify rare structural variants segregating with longevity phenotypes
• Link methylation differences to gene regulation, aging trajectories, or disease resistance
• Integrate findings with phenotypic and clinical data to generate new hypotheses for healthy aging

Posted In: PACB